Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience
World Journal of Urology · 2021-10 · 39 (10) · 3867-3873
DOI: 10.1007/s00345-021-03685-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Urology, online erschienen am 03.04.2021. Verfasst von Nicola Frego und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Humanitas Clinical and Research Center-IRCCS, Rozzano, Italy. nicola.frego@humanitas.it. Hauptthemen laut MEDLINE: Perineum. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation (TPLA) as a new minimally invasive surgical therapy (MIST) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Under local anesthesia and conscious sedation up to two laser fibers for each prostatic lobe were inserted under US-guidance by a percutaneous approach. TPLA was performed using a continuous wave diode laser (SoracteLite-EchoLaserX4) able to generate a light-induced thermal heating and subsequent coagulative necrosis of the prostatic tissue. Patients were evaluated at 3, 6, and 12 months after TPLA. RESULTS: Twenty-two consecutive patients were prospectively enrolled (median age 61.9 years). All procedures were well tolerated and no procedural complications were recorded. Median catheterization time was 7 days, while the median hospitalization time was 1 day. Three out of twenty-two patients (13.6%) experienced acute urinary retention and two (9.1%) of them urinary tract infection requiring major antibiotic treatment. At 3, 6, and 12 months, median prostate volume significantly decreased by a - 21.3%, - 29%, and - 41%, respectively. At the same time point, median IPSS was 8 (- 63.6%), 5 (- 74%), and 6 (- 75%), while median QoL score was 1 in all the scheduled timepoints of follow-up. The median postoperative Qmax at 3, 6, and 12 months improved by + 57.8%, + 98%, and + 115.8%, respectively. Ejaculatory function was preserved in 21 out of 22 patients (95.5%). CONCLUSIONS: TPLA of the prostate appears to be a promising MIST for BPH. Long-term results and comparative studies against standard treatments are warranted before implementations of this technique in the urologist's armamentarium.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Humanitas Clinical and Research Center-IRCCS, Rozzano, Italy. nicola.frego@humanitas.it.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. nicola.frego@humanitas.it.
- Department of Urology, Humanitas Clinical and Research Center-IRCCS, Rozzano, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
Zitieren
APA
Frego, N., Saita, A., Casale, P., Diana, P., Contieri, R., Avolio, P. P., Lazzeri, M., Hurle, R., Buffi, N. M., Guazzoni, G. F., & Lughezzani, G. (2021). Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience. World Journal of Urology, 39(10), 3867-3873. https://doi.org/10.1007/s00345-021-03685-7
Vancouver
Frego N, Saita A, Casale P, Diana P, Contieri R, Avolio PP, et al. Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience. World Journal of Urology. 2021;39(10):3867-3873. doi:10.1007/s00345-021-03685-7
BibTeX
@article{Frego2021,
author = {Frego, Nicola and Saita, Alberto and Casale, Paolo and Diana, Pietro and Contieri, Roberto and Avolio, Pier Paolo and Lazzeri, Massimo and Hurle, Rodolfo and Buffi, Nicolò Maria and Guazzoni, Giorgio Ferruccio and Lughezzani, Giovanni},
title = {Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience},
journal = {World Journal of Urology},
year = {2021},
volume = {39},
number = {10},
pages = {3867--3873},
doi = {10.1007/s00345-021-03685-7}
}
EUVIMED